In conclusion, this study showed the inhibition of EGFR-mediated cell proliferation and the inhibition of tumour angiogenesis by gefitinib in anaplastic thyroid cancer cell lines. This evidence concerns the gene EGFR and thyroid gland undifferentiated (anaplastic) carcinoma.